Drug intelligence / Profile preview

SBRX13

Development stage: Preclinical
Lead developer: Stramsen Biotech
Modality: Small Molecules

Overview

SBRX13 is a plant-based drug candidate developed by Stramsen Biotech Inc. for the treatment of male reproductive health conditions. It is specifically designed to address male infertility, erectile dysfunction, and low testosterone levels. The therapeutic mechanism involves promoting the development and maturation of sperm, stimulating the endogenous production of testosterone, and improving erectile function. As part of Stramsen's SBRX series of natural plant-based medicines, SBRX13 is one of several candidates in the company's pipeline being advanced toward clinical trials.

Beyond the preview

Go deeper on SBRX13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBRX13.

Explore the full profile